SCHEMBL5263558

SCHEMBL5263558

CN(C)c1ccc(NC(=O)c2ccc(Cl)c(Nc3ncccc3-c3ncccn3)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BRAF P15056 10/20 0.54
MAPK14 Q16539 2/20 0.49
EGFR P00533 1/20 0.49
KDR P35968 2/20 0.48
TEK Q02763 2/20 0.48
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
FGFR2 P21802 1/20 0.44
FGFR3 P22607 1/20 0.44
CSF1R P07333 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1265258 0.88 TEK (0.66) BRAFMAPK14EGFRKDRTEK
SCHEMBL1265444 0.78 TEK (0.81) BRAFMAPK14KDRTEK
SCHEMBL1265113 0.75 TEK (0.70) BRAFMAPK14KDRTEK
Acetic Acid SCHEMBL2684357 0.74 TRPV1 (0.60) BRAFNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL1264685 0.73 TEK (0.81) BRAFMAPK14KDRTEK
SCHEMBL1264350 0.71 KDR (0.67) BRAFMAPK14KDRTEKSMN1; SMN2
SCHEMBL30132679 0.71 MAPT (0.57) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL2963586 0.70 CSF1R (0.57) BRAFMAPK14EGFRNPC1RAB9A
SCHEMBL1265486 0.70 BRAF (0.67) BRAFMAPK14KDRTEK
SCHEMBL1264803 0.70 TEK (0.77) BRAFMAPK14KDRTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751136-A2 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC. (US) 2007-02-14 EP disclosed
WO-2005113494-A2 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC. (US) 2005-12-01 WO disclosed